WealthTrak Capital Management LLC Invests $26,000 in Johnson & Johnson (NYSE:JNJ)

WealthTrak Capital Management LLC purchased a new stake in Johnson & Johnson (NYSE:JNJ) in the 4th quarter, Holdings Channel.com reports. The institutional investor purchased 179 shares of the company’s stock, valued at approximately $26,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in JNJ. Principal Financial Group Inc. raised its stake in Johnson & Johnson by 10.5% in the 3rd quarter. Principal Financial Group Inc. now owns 3,472,312 shares of the company’s stock worth $562,723,000 after purchasing an additional 329,473 shares in the last quarter. United Bank increased its holdings in shares of Johnson & Johnson by 5.6% during the third quarter. United Bank now owns 3,788 shares of the company’s stock worth $614,000 after purchasing an additional 202 shares during the period. Algert Global LLC acquired a new stake in shares of Johnson & Johnson in the third quarter valued at approximately $721,000. Suvretta Capital Management LLC boosted its stake in shares of Johnson & Johnson by 53.7% in the third quarter. Suvretta Capital Management LLC now owns 138,447 shares of the company’s stock valued at $22,437,000 after buying an additional 48,350 shares during the period. Finally, Isthmus Partners LLC grew its position in Johnson & Johnson by 1.8% during the third quarter. Isthmus Partners LLC now owns 97,495 shares of the company’s stock worth $15,800,000 after buying an additional 1,765 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. The trade was a 2.60 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Robert J. Decker sold 6,999 shares of the stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the transaction, the vice president now directly owns 21,001 shares in the company, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Price Performance

Shares of JNJ opened at $163.63 on Friday. The business has a 50-day moving average of $158.68 and a 200-day moving average of $156.21. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The company has a market capitalization of $394.32 billion, a price-to-earnings ratio of 24.61, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. During the same quarter last year, the business earned $2.29 EPS. The company’s revenue was up 5.3% compared to the same quarter last year. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were given a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.03%. The ex-dividend date of this dividend was Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on JNJ shares. Royal Bank of Canada reiterated an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a research report on Wednesday, February 19th. Wells Fargo & Company cut their price target on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Guggenheim reaffirmed a “neutral” rating on shares of Johnson & Johnson in a research note on Monday, March 10th. Morgan Stanley lowered their target price on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Finally, StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $171.33.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.